Enrolment In the Phase III TAHOE study has been halted due to shorter overall survival in the Rova-T arm compared with the control arm.
AbbVie Inc. has reported disappointing clinical data with its investigational antibody-drug conjugate (ADC), Rova-T (rovalpituzumab tesirine), in the Phase III TAHOE study which was evaluating its use as a second-line therapy for patients with advanced small-cell lung cancer (SCLC).
The study has been halted on the recommendation of the trial's independent data monitoring committee because of a shorter overall...
In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
